PMID: 6167274Jun 1, 1981Paper

Accumulation of intermediate density lipoprotein in plasma after intravenous administration of hepatic triglyceride lipase antibody in rats

Atherosclerosis
T Murase, H Itakura

Abstract

In an attempt to define the role of hepatic triglyceride lipase in plasma lipoprotein metabolism, in vivo experiments using an antibody specifically prepared against this enzyme were conducted in rats. The antibody gamma globulins were injected into rats three times during a 40 min period. Control rats received non-immune rabbit gamma globulins prepared in the same way as the immune gamma globulins. After treatment, blood was taken and the plasma was separated. Plasma lipoproteins were fractionated by ultracentrifugation into VLDL, IDL, LDL and HDL. Treatment of recipient rats with the antibody significantly increased cholesterol, phospholipid and protein concentrations in the IDL fraction. These concentrations were also elevated in the LDL fraction. However, we speculate that this increase represents the accumulation of small remnants rather than bona fide LDL. VLDL compositions in antibody-treated rats did not differ from those in control animals. In HDL, only the phospholipid level was elevated in antibody-treated rats. The data of the present study indicate that hepatic triglyceride lipase mediates the catabolism of remnant lipoproteins by the liver.

References

Jul 1, 1979·The Biochemical Journal·T KuusiP K Kinnunen
Aug 15, 1977·Clinica Chimica Acta; International Journal of Clinical Chemistry·M TakayamaI Tanimizu
Sep 17, 1971·Biochemical and Biophysical Research Communications·R V HayR W Wissler
Mar 1, 1970·The Journal of Clinical Investigation·T G Redgrave
Nov 1, 1968·Clinica Chimica Acta; International Journal of Clinical Chemistry·M J Fletcher
Jan 15, 1980·Biochemical and Biophysical Research Communications·H JansenW C Hülsmann
Aug 1, 1980·Metabolism: Clinical and Experimental·T Murase, H Uchimura
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯

Citations

May 17, 1990·Klinische Wochenschrift·G FeussnerR Ziegler
Jul 20, 1982·Biochimica Et Biophysica Acta·P H FrostR J Havel
Mar 27, 1984·Biochimica Et Biophysica Acta·B Landin, A Nilsson
Mar 7, 1984·Biochimica Et Biophysica Acta·J S TwuM C Schotz
Jan 9, 1985·Biochimica Et Biophysica Acta·M Y ChuangP S Roheim
Apr 15, 1986·Biochimica Et Biophysica Acta·H M LabodaM C Phillips
May 13, 1987·Biochimica Et Biophysica Acta·O Ben-ZeevM C Schotz
Apr 3, 1989·Biochimica Et Biophysica Acta·M A ClayP J Barter
Jan 23, 1989·Biochimica Et Biophysica Acta·H JansenJ C Birkenhäger
Jan 16, 1990·Biochimica Et Biophysica Acta·F SultanS Griglio
Jan 24, 1992·Biochimica Et Biophysica Acta·B StaelsJ Auwerx
Dec 31, 1993·Clinica Chimica Acta; International Journal of Clinical Chemistry·K NakajimaE Campos
Jun 1, 1985·Metabolism: Clinical and Experimental·T Murase, S Inoue
Oct 1, 1983·Molecular and Cellular Endocrinology·N R NicholsJ W Funder
Apr 21, 1999·Progress in Lipid Research·D A Chappell, J D Medh
Oct 13, 1998·Diabetes Research and Clinical Practice·S KadoN Nagata
Aug 1, 1987·Baillière's Clinical Endocrinology and Metabolism·J R Patsch
Aug 1, 1987·Baillière's Clinical Endocrinology and Metabolism·M R Taskinen, T Kuusi
Oct 1, 1995·Baillière's Clinical Endocrinology and Metabolism·J D Barth
Aug 5, 1982·The New England Journal of Medicine·P J NestelM H Tan
Aug 30, 1994·Proceedings of the National Academy of Sciences of the United States of America·J FanJ M Taylor
Jun 30, 1998·Current Opinion in Lipidology·S Santamarina-FojoM Amar
Feb 1, 1993·Kidney International·J JovenJ D Brunzell
Feb 1, 1990·Clinical Biochemistry·M K Chan
Feb 1, 1987·American Heart Journal·M J Tikkanen, E A Nikkilä
Feb 1, 1983·Metabolism: Clinical and Experimental·T MuraseH Uchimura

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.